Aurobindo Pharma, Glenmark recall mutliple products in US
New Delhi: Glenmark Pharmaceuticals and Aurobindo Pharma are recalling multiple products in the US market due to various reasons like deviation from standard manufacturing protocols and presence of foreign substance in one of the affected lots.
As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Glenmark's US-based unit is recalling various products in the US market.
The company is recalling 28,658 cartons of Fulvestrant injection (250 mg/5 ml), a medicine used to treat breast cancer, due to "lack of assurance of sterility", the US health regulator noted in the report.
Glenmark Pharmaceuticals Inc, USA is also recalling 9,552 bottles of Naproxen Sodium Tablets (275 mg), a pain relieving medicine, due to "CGMP (Current Good Manufacturing Practice) deviations".
The company is also recalling around 31,500 bottles of the product in 550 mg strength.
Read also: Granules India, Jubilant Cadista recall products in US
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.